File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1093/humrep/17.7.1738
- Scopus: eid_2-s2.0-0036069479
- PMID: 12093832
- WOS: WOS:000176786000013
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation
Title | Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation |
---|---|
Authors | |
Keywords | Medical abortion Mifepristone Misoprostol Sublingual |
Issue Date | 2002 |
Publisher | Oxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/ |
Citation | Human Reproduction, 2002, v. 17 n. 7, p. 1738-1740 How to Cite? |
Abstract | Background: A combination of mifepristone and misoprostol provides an effective method of medical abortion for early pregnancy. A new route of administration of misoprostol, the sublingual route, was investigated in this study. Methods: One hundred women who requested legal termination of pregnancy up to 63 days were given 200 mg of oral mifepristone followed 48 h later by 800 μg (4 × 200 μg tablets) of sublingual misoprostol. Results: Ninety-four women (94%) had a complete abortion with this regimen. There was one ongoing pregnancy. The median duration of vaginal bleeding was 15 days. There were no serious complications. However, lower abdominal pain, diarrhoea, chills and fever were the commonest side-effects with incidences of 89, 42, 38 and 79% respectively. Conclusions: The combination of mifepristone and sublingual misoprostol is effective for medical abortion up to 63 days gestation. Randomized trials are required to compare its efficacy and side-effect profile with vaginal misoprostol. |
Persistent Identifier | http://hdl.handle.net/10722/173259 |
ISSN | 2023 Impact Factor: 6.0 2023 SCImago Journal Rankings: 1.852 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tang, OS | en_US |
dc.contributor.author | Xu, J | en_US |
dc.contributor.author | Cheng, L | en_US |
dc.contributor.author | Lee, SWH | en_US |
dc.contributor.author | Ho, PC | en_US |
dc.date.accessioned | 2012-10-30T06:28:51Z | - |
dc.date.available | 2012-10-30T06:28:51Z | - |
dc.date.issued | 2002 | en_US |
dc.identifier.citation | Human Reproduction, 2002, v. 17 n. 7, p. 1738-1740 | en_US |
dc.identifier.issn | 0268-1161 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/173259 | - |
dc.description.abstract | Background: A combination of mifepristone and misoprostol provides an effective method of medical abortion for early pregnancy. A new route of administration of misoprostol, the sublingual route, was investigated in this study. Methods: One hundred women who requested legal termination of pregnancy up to 63 days were given 200 mg of oral mifepristone followed 48 h later by 800 μg (4 × 200 μg tablets) of sublingual misoprostol. Results: Ninety-four women (94%) had a complete abortion with this regimen. There was one ongoing pregnancy. The median duration of vaginal bleeding was 15 days. There were no serious complications. However, lower abdominal pain, diarrhoea, chills and fever were the commonest side-effects with incidences of 89, 42, 38 and 79% respectively. Conclusions: The combination of mifepristone and sublingual misoprostol is effective for medical abortion up to 63 days gestation. Randomized trials are required to compare its efficacy and side-effect profile with vaginal misoprostol. | en_US |
dc.language | eng | en_US |
dc.publisher | Oxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/ | en_US |
dc.relation.ispartof | Human Reproduction | en_US |
dc.rights | Human Reproduction. Copyright © Oxford University Press. | - |
dc.subject | Medical abortion | - |
dc.subject | Mifepristone | - |
dc.subject | Misoprostol | - |
dc.subject | Sublingual | - |
dc.subject.mesh | Abortifacient Agents, Nonsteroidal - Administration & Dosage - Adverse Effects - Pharmacology | en_US |
dc.subject.mesh | Abortifacient Agents, Steroidal - Administration & Dosage - Adverse Effects - Pharmacology | en_US |
dc.subject.mesh | Abortion, Induced - Methods | en_US |
dc.subject.mesh | Administration, Oral | en_US |
dc.subject.mesh | Administration, Sublingual | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Drug Synergism | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gestational Age | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Mifepristone - Administration & Dosage - Adverse Effects - Pharmacology | en_US |
dc.subject.mesh | Misoprostol - Administration & Dosage - Adverse Effects - Pharmacology | en_US |
dc.subject.mesh | Pilot Projects | en_US |
dc.subject.mesh | Pregnancy | en_US |
dc.subject.mesh | Pregnancy Trimester, First | en_US |
dc.title | Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation | en_US |
dc.type | Article | en_US |
dc.identifier.email | Ho, PC:pcho@hku.hk | en_US |
dc.identifier.authority | Ho, PC=rp00325 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1093/humrep/17.7.1738 | - |
dc.identifier.pmid | 12093832 | - |
dc.identifier.scopus | eid_2-s2.0-0036069479 | en_US |
dc.identifier.hkuros | 82747 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0036069479&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 17 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.spage | 1738 | en_US |
dc.identifier.epage | 1740 | en_US |
dc.identifier.isi | WOS:000176786000013 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Tang, OS=7006723402 | en_US |
dc.identifier.scopusauthorid | Xu, J=7407007994 | en_US |
dc.identifier.scopusauthorid | Cheng, L=34869443100 | en_US |
dc.identifier.scopusauthorid | Lee, SWH=26030998000 | en_US |
dc.identifier.scopusauthorid | Ho, PC=7402211440 | en_US |
dc.identifier.issnl | 0268-1161 | - |